Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial
Details : AL101 (GSK4527226) is an investigational monoclonal antibody targeting the sortilin receptor, developed for treating early Alzheimer’s disease, including mild cognitive impairment and dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024
Details : AL101 is an investigational small molecule Gamma Secretase Inhibitor that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in the Phase 2 ACCURACY clinical studies in patients with adenoid cystic carci...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2022
Details : AL101 is an investigational small molecule gamma secretase inhibitor that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, is currently being evaluated in Phase 2 ACCURACY clinical studies in patients with adenoid cystic carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2022
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial
Details : AL101 is designed to inhibit the expression of Notch gene targets by blocking the final cleavage step by the gamma secretase required for Notch activation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2021
Details : The ongoing Phase 2 ACCURACY clinical trial is an open-label, single-arm, multi-center study to assess the clinical activity of AL101. Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control r...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2020
Details : Interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma harbouring Notch activating mutations will be presented in an oral presentation at the European Society for...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2020
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Details : AL101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Cancer Biotech Ayala Pharmaceuticals Prices Upsized US IPO at $15 midpoint
Details : Ayala's lead candidate AL101 is an injectable small molecule gamma secretase inhibitor (GSI) in an ongoing Phase 2 trial for recurrent cystic carcinoma in patients with Notch pathway mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 07, 2020
Oncology biotech Ayala Pharmaceuticals files for a $50 million IPO
Details : Ayala plans to use the public funding mainly to advance clinical trials for its leading drugs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 06, 2020
Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101
Details : The designation is based on the initial data from Phase 2 ACCURACY clinical trial, demonstrating that AL101 has been well tolerated in patient population.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 03, 2020